untitled design

Albert Burla: Named CEO of the Year by CNN

Pfizer CEO Albert Bourla has been named CEO of the Year by CNN Business.

The Covid-19 pandemic may not be over yet, but life in many areas has returned to something that seems normal to many. This is largely due to the fact that there are now many more vaccines against coronavirus, including Pfizer.

And that’s one of the main reasons why CNN Business named Pfizer CEO Albert Burla’s CEO of the year.

CNN Business looked at several other CEOs including AMD’s Lisa Su, Ford’s Jim Farley, Lowe’s Marvin Ellison, Goldman Sachs’ David Solomon, Alphabet’s Sundar Pichai and SpaceX’s Elon Musk Person of the Year Time.

But Burla was CNN’s choice for everything Pfizer did in a year when Covid vaccines became mainstream (the vaccine was even named Word of the Year by the Merriam-Webster Dictionary) and helped stabilize the US and global economies.

“Pfizer has done a lot of good for humanity and we are very, very proud of that,” Bourla told CNN Business. “Not only have we been able to save so many lives but we are enjoying high levels of corporate reputation right now. People like us.”

The Pfizer / BioNTech vaccine was the first to be approved in the United States for children ages 5 to 11. But many parents of even younger children are now waiting to know when a vaccine for babies, toddlers and preschoolers will be approved.

Burla said he understands the frustration of parents who are fully vaccinated but unable to protect their youngest children. “We are working very hard on this to make sure we can provide a solution to it,” he said.

In addition, Pfizer has developed a pill that could drastically reduce the risk of serious complications, hospitalization and death for people with coronavirus

The Omicron mutation has raised concerns around the world about the effectiveness of current vaccines. However, Burla told CNN Business that he believes the Pfizer / Biontech vaccine will control the Omicron strain “quite well,” especially if people have taken two doses and the booster.

He acknowledged, however, that Pfizer may need to launch a new vaccine to target specific micronutrients or other future variants. Burla said Pfizer was already developing a vaccine targeting Omicron and that it believed it could be tested and submitted to regulators for approval by March.

Read also:

.

Source From: Capital

You may also like

Ethena Labs project will hold an airdrop
Top News
David

Ethena Labs project will hold an airdrop

The Ethereum-based decentralized stablecoin (USDe) protocol team, Ethena Labs, announced an airdrop on April 2, 2024. We are excited to

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular